ClinicalTrials.gg
Not yet recruitingNCT07472608Updated Mar 16, 2026

Obesity Medicine Bank of the Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval)

An observational study in Obesity, Metabolic Abnormalities and Health, sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Institut universitaire de cardiologie et de pneumologie de Québec, University Laval · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 575 studies in Obesity with a site in Canada — 102 open to participants now, 151 under way, 47 of them phase 3. Obesity · Canada.

Planned enrollment
Largest of 91
25,000 · median 52
Started
2026
with 53 others
Observational
91 of 575
16 open now
Primary completion
2051-06
later than 149 of 150 live
Registered
540th of 575
by date

Among the 575 studies in Obesity with a site in Canada, this one has the largest planned enrollment of the 91 observational ones that give a count, is one of 54 that started in 2026, is one of 91 observational ones, reaches primary completion later than 149 of the 150 other live ones, and was the 540th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

102 of the 575 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 575 studies in Obesity with a site in Canada, or all of them as a file.
02

Study summary

Obesity medicine, or bariatric medicine, focuses not only on the biological and behavioral aspects, but also on the environmental and social factors that contribute to the development of obesity. Many diseases are associated with obesity, such as type 2 diabetes, hypertension, cardiovascular diseases, numerous cancers, gynecological disorders, etc. Focusing on obesity medicine is crucial for improving patients' quality of life, reducing healthcare costs, and developing effective prevention strategies. The Quebec Heart and Lung Institute - Laval University (IUCPQ-ULaval) maintains a clinical database and biological material bank for studying the multidisciplinary management of obesity and its complications.

A biobank is a collection of information, clinical or biochemical data (including radiological, cardiac, and genetic data), and blood samples concerning donors. The information that can be collected includes, for example, age, sex, diagnosis, progression or treatment of a medical condition, medications, DNA, etc. DNA is a molecule present in all cells and contains all the information necessary for the development and functioning of our body.

This bank aims to better characterize patients' profile receiving follow-up care in obesity medicine, identify predictive factors of success or failure of interventions and adapt management strategies according to specific needs. The collected data and blood samples will be used in several research projects with the following objectives:

  1. To document the socioeconomic, demographic, clinical, radiological, genetic, and biochemical characteristics of patients living with obesity and requiring medical follow-up at the bariatric medicine clinic at the IUCPQ-ULaval
  2. To explore the effects or associations of genetic and biochemical determinants on health in the context of obesity
  3. To gain a better understanding of the pathophysiology and genes involved in obesity and associated metabolic abnormalities
  4. To evaluate the clinical utility of non-invasive biomarkers in the screening of preclinical obesity and its comorbidities and/or
  5. To evaluate the effectiveness of medications, health behavior changes, and bariatric surgery in order to develop optimal interventions aimed at improving the health and medical management of people with obesity.
03

Conditions studied

  • Obesity
  • Metabolic Abnormalities
  • Health

Browse trials for

Keywords

  • Biobank
  • Clinical data
  • Radiological data
  • Genetic data
  • Biochemical data
  • Cardiac data
  • Blood samples
  • Prospective patient registry
  • Bariatric medicine
  • Health
  • Obesity medicine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient starting follow-up at the Bariatric Medicine Clinic of the IUCPQ-ULaval.

Eligibility criteria

To be included in the registry (database + biobank), a person must first be referred to the Bariatric Medicine Clinic at the IUCPQ-ULaval and meet several criteria:

  1. Be over 18 years of age
  2. Meet at least one of the following five criteria:

    1. ≥30 kg/m2 with or without comorbidities (preclinical or clinical obesity);
    2. Require weight loss related to a transplant, bariatric surgery, or another type of surgery (e.g., hernia repair, orthopedic surgery, neurosurgery, etc.);
    3. History of bariatric surgery resulting in weight regain of at least 15% of the total weight lost;
    4. History of bariatric surgery resulting in weight loss deemed insufficient by the treating medical team;
    5. Having undergone bariatric surgery with complications related to it (i.e., flushing syndrome or hypoglycemia, nephrolithiasis, return of comorbidities in remission, abnormalities in phosphocalcic balance and vitamin deficiencies).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25,000 participants (estimated)
Target follow-up
25 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Obesity medicine cohort

    This cohort includes patients followed in bariatric medicine at IUCPQ-ULaval

    Other: Behavioral and Pharmacological Treatments

Interventions

  • OtherBehavioral and Pharmacological Treatments

    Behavioral and pharmacological treatments are part of the standard of care and will vary among individuals based on their specific needs.

06

What researchers measure

Primary outcomes

  1. Success or failure of obesity medicine interventions

    1. Anthropometric Parameters: weight and height combined to obtain BMI (kg/m\^2). Waist circumference (cm); Body composition assessed by bioelectrical impedance analysis 2. Cardiometabolic Parameters and Comorbidities: Hepatic steatosis and fibrosis assessed by controlled attenuation parameter (CAP) and liver stiffness measurement (transient elastography); Liver biochemical parameters (e.g., ALT, AST, GGT); Lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides); Inflammatory markers (as available in medical records); Glycemic parameters (fasting glucose, HbA1c, insulin, as available); Polysomnography parameters (when available); Echocardiographic parameters (when available) 3. Adoption of Lifestyle Intervention: Documented adherence and engagement in prescribed lifestyle interventions, as reported in medical charts 4. Quality of Life: Clinician-documented quality-of-life assessment, as recorded in medical charts 5. Mental Health Parameters: As recorded in medical charts

    Time frame: Baseline to 15-year follow-up. Follow-up is based on standard care consultations which vary from a patient to another

07

Study locations

1 site
  • Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec
    Québec, Quebec G1V 4G5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jun 2051, 300 months later.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 300 months is above that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2026
First posted
Mar 16, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Jun 2051
CompletionEst.
Jun 2051
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07472608
Lead sponsor
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Responsible party
Fannie Lajeunesse-Trempe (Clinician-Researcher, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval) — Principal investigator
First posted
Mar 16, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Jun 2051 (estimated)
Completion
Jun 2051 (estimated)
Last update
Mar 16, 2026

Study contacts

Audrey St-Laurent, PhD
Contact
audrey.st-laurent@criucpq.ulaval.ca
418-656-8711 ext. 2681
Fannie Lajeunesse-Trempe, MD PhD FRCPC
Contact
fanny.lajeunesse-trempe.1@ulaval.ca
418-656-8711 ext. 8052

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion